HIF1A and familial pancreatic carcinoma: New therapeutic strategies by targeting hypoxia and HIF-1α pathways using RNA interference or specific inhibitory agents in pancreatic cancer- and metastasis-initiating cells and their differentiated progenies for improving current therapies have recently been investigated under normoxic and hypoxic conditions (Tables 1 and 2) [11, 62–65, 290].